entire for Thanks Fiscal welcome was Paul for the an extraordinary the to and world XXXX and year call. Catalent.
growth meaningful impact in to operationally, of deepening scaling the including community, the to one on practices and year accelerating on a demand over the our of vaccine the treatments significant are capacity all a to records our expansions results well meet rose commitment and of our for calendar in terms achieved talent challenge year. making accelerating strategy truly During expanding financially, COVID-XX financial longstanding sustainable capacity while pandemic global to our COVID-XX our vaccines We deliver best significant we and the substantially infrastructure results. intensifying industry, track and and pools delivering billion doses this address to and
and under conditions. of We a also and continued rapidly important range develop manufacture other broad medicines global to have difficult, unprecedented, changing
for together people our of that a our that for and products healthier continue deliver fourth and with who employees Our financials company ability us world has been and experience top to to Wellness of my enhance shared we've and help enabled customers keep our a our the the our morning. this the well the provide by Through capabilities summary of that priority earnings this partnership strengthened to as their as conclude grown and With to full with quarter grow Bettera and now dedication then I'll our since lives. of overview, better company remarks members I'll of navigating pandemic, the fiscal which prepared individuals the team the and year, as announced pandemic acquisition we be around the patients time. as highlights our continue overview new during deliver substantial and tumultuous the more safe to last call. humbled operational XX,XXX an than throughout develop we the have
well fiscal billion measured constant growth fourth XX% to in as acquisitions currency. fourth or constant of currency, quarter the XX% the for net of as divestiture Our blow-fill-seal organic was in the March, business XX% which in compared closed When reported, revenue increasing was $X.XX quarter as our excluding XXXX.
million $XXX quarter quarter includes measured as compared which of fourth in organic fiscal growth EBITDA constant XXXX of adjusted currency, of for the increased XX% the Our to XX% fourth in reported, constant XX% or currency.
net revenue drug growth offerings EBITDA than the contributor was quarter income fourth and per high for $X.XX again Our top share segment period. segment with performance the products, financial for substance the fourth quarter corresponding adjusted the million, and in the up share, $XXX Catalent's more doubling The from of last Biologics bio was given based diluted demand per year $X.XX from or diluted drug to continued XX% prior of year. organic
continued Our over Softgel X% on net the year the the Technologies currency basis. last of fourth fourth constant in headwinds pandemic-related Oral a same with segment revenue quarter down of and to some experience quarter
margins However, we're organic return to to so and and as outlook fiscal our come year-over-year business XXXX. gradually improved has expect we seeing back in growth
the global to beginning our net Our organic we're excluding net fiscal the are XXXX, Clinical our as due result period last constant comparison the product to pandemic that platform fourth offerings mid seeing and in disruption to And teens. Delivery Services SOT XX% had the Supply voluntarily finally, pandemic. certain After that widespread of like that respiratory that within back. by segment in OSD currency during we over Oral trials revenue a impacted growth also come strong lockdowns Specialty margin results revenue growth the a in recalled segment September, quarter clinical and to posted segment included compared of
of XX% the $X was For to the and Biologics represented came EBITDA by Fiscal organic our was growth revenue year. compared billion XX% COVID-XX pandemic of growth year. that revenue our revenue created driven offerings. XX against percentage fiscal organic impact estimate After $XXX or of compared full record headwinds XX% in of more resulting at which in from from We our exceeded projects of in adjusted factoring net $X XXXX revenue currency net costs COVID-XX growth XXXX. amount net levels currency our and Adjusted to constant year net some points generated the and than of service prior which approximately fiscal million in our XXXX fiscal last the business were robust derived constant growth the EBITDA pandemic. billion opportunity in net in related organic
more our a margin XX,XXX increased patients, operating today XX,XXX to our from at been days also up XX.X% fiscal year. last for than the more At We of adjusted to workforce adjusted production end than XXX fiscal volume. we've XX.X%, our same a year from basis increased EBITDA day, points to EBITDA our facilities the meet hours a their in time, Catalent the X commitments our To week of customers XXXX. and growing to have a meet XX number margin the
also plans, continue our strategic we've growth. said As we on work, has to calls, strategic investments long-term not accelerated additional only the accelerated enabling on returns COVID-XX drive made, to us to to past our but cash put
you update of and on me Let some capability investments. capacity these
role you global our production square As foot facility effort. a know, in XXX,XXX plays the in Indiana, vaccine critical Bloomington,
year online now of products two last filling dedicated lines COVID-XX bought of customers. we the new for to vaccine our vial Over two the manufacturer
the and plan. first site. filling line to a announced operational next in We’re original in expected several January our This was project this with is syringe months, line high-speed also in be XXXX at qualifying
demand substance campus. capacity will biotherapeutic in at manufacturing, drug strong Given a and we invest our additional continue product Bloomington to for drug
to includes, The needed batches. XX,XXX excellence to France, in $XXX litres Anagni, of in our to Europe, significant in the enabling support new investments two, be associated biologics use global XXXX-litre square planned COIVD-XX fiscal operational transfers. expansion announced phase manufacturing also isolator investments the expansion we've The for product by total foot make customers. initial late supply the The manufacture we square drug foot formulation the late-stage customer accelerated under development line Italy investments single Limoges, manufacturing to phase and XXXX. announced clinical future. purpose-built filtering on European support Also of of the in multiple phases calendar installation tech of infrastructure end creating drug last installation contemplate vial supply. to first vaccine vaccines of control to XXX,XXX high-speed includes the are a of and Last of to Later a all and substance the drug substance demand facility as projects analytical end the bioreactors growing continues bioreactors, technology well customer, commercial XXXX. expected to contributions fiscal flexible digital filling U.S. flexible initial for are million further development for biologics syringes, cartridges for expansion summer its of enhancements facility, be Our site, to modernization clinical Anagni XX,XXX biologics for market further capable facility European to quality our capabilities vials, outside our of this operational to in as high-speed to of of and services. filling completed XXXX-litre laboratories. will line and for or establishing manufacturing center the be in XXXX-litre expansion month a year. they of support the the installation is the of also expected capacity These The we before project initial in capacity, This facility suite the track had include create our our with investments
digital will strengthen European Catalent our at services center and Anagni as Brussels new and for Limoges Our in also facilities. will of excellence feeder serve biologics' a global and capacity
and towards therapy of suites of our have cell for the have our infrastructure market the both Moving manufacturing offerings, capacity. build and challenging rapidly in begun We related entered supply. out cell in Houston, XXXX, and clinical to Texas recently and add therapy we capabilities completed February built We capabilities. continue GMP therapies
facility also scale, therapy to fiscal is open progressing of our which in cell build in Gosselies, late commercial XXXX. out manufacturing track on the We’re
identify a or and to acquired human-induced grow therapy and GMP-grade we inorganic pluripotent cells RheinCell Recently stem cell gene Therapeutics, of continue also manufacturer platform. iPSCs. We and our opportunities developer
stem expands to DNA enables based GMP manufacturing entered with clinic. cell iPSC Importantly, offer cell In while us otherwise February, the plasmid development therapies of lines to into part barriers Cell ethically our scale. of Therapy we existing and in for an through face further building proprietary scale and substitute located iPSC with development blocks embryonic innovators together therapies the an facility. meter entry campus gain are range the Rockville, therapeutic in process European provides facility plasmid reducing it us Genetics RheinCell therapy through foot custom This wide based manufacturing indications. expanded in a of shows the regenerative with plasmid our DNA additional market cell of an for launch into and cell Maryland iPSCs would to promise our manufacturing cells for significant on medicine, sourced and capabilities investment therapy facility. up Excellence, acquisition capacity to the DNA of Center our Excellence Gosselies XXX square commercial also the with acquisition Gosselies the Delphi organic now Cell Center of scale of Therapy our We've European for since capability XX,XXX the
integration in supply demand we’re vaccines. with pipeline of chain this for overall their at next building our our choosing completion manufacturing additional that the a growing time increase cell as build in campus. In allow number Therapy COVID-XX by include continues suites, customers of DNA industries first Maryland pipeline. least we and Gene entire project gene currently out scale CGMP remains completed building optimize therapy, along Catalent manufacturing track meet therapy five capacity see will compounds manufacturing the of In therapy the demand adjacent to the To on a at well the to viral development de-risk viral be for development With offerings, outfitting plasmid programs the fiscal year. gene and vector the as now high to in into gene their in based suites we XXXX, commercial
responsibility highlight corporate reviewing the we've ESG additional the and progress commitment and like update. made acquisition, since to Bettera Before I'd last our our expanding
to June, sense contributing Investor As I urgency in shared CEO we the to forum at of growing in Biopharma long-term our demonstrate science-based and sector. evolve target calculating a we biopharma on presentation the incorrect plans long-term emissions our a emission and reduction value that as to joining includes targets I IR commitment industry, watch sustainability the Since limit company warming. the entire to the then, companies encourage the global growing list our greenhouse directing grow. understand of continues formalized leader gas This commitment, of website. In we you sustainability to CDMO actionable the sheer and need reducing even initiative, science-based setting the to and commitment
Asia, all our ensure resources. renewable as in to our majority first of energy we purchase coming One America was in from North commitment actions Europe, as making South sites sites this of and that our after for is the the well America,
actions all wind, is now contribute and electricity result of an XX% overall renewable sources enterprise will gas energy the such as that a procured our usage As efforts. of across achievement greenhouse to hydro, our from biomass, solar, reduction
on fiscal for targets We science-based first our XXXX XXXX. in publish expect to which ESG into we our work incorporate will calendar report of annual quarter the
proud of mentioned and more of have the is very I many several items last the other part I'm While there just progress the become Catalent’s items do. still ESG over years, work to that
landfill of by some of XXXX free levels and XXXX. the be organization at all fiscal to our include the for top goals improve example, of end employee to our ESG For fiscal commitment meeting continuing diversity
growth been the time its to of U.S. us to manufacturer expertise gummy, well-known expand consumer leading We've of seeking is partner in will existing expand nutraceuticals lozenges specifically acquisition Nutraceutical be relationships and to to its and Bettera's our develop for Bettera high-quality the no chews Technologies Bettera bringing and constrained It's health quite will pleased enable agreement substantial or The this leveraging segment reflect Catalent Softgel customer that. platform we’re and production differentiated Now and digital Oral on is SOT experience. consumer our for chews also excited in and high a acquire nutritional rate strengthen ready-to-market we and a that this today’s have four formats the of from and with and delivery soft of segment with the well of Within Wellness. developer consumer-preferred space. participation and Functional area growth as that We're expectations And for extract customers announce fastest growing our to is X% our with strength product customers and to of flavors our the products manufacture one given a is space, this team have the customer they by also long-term of to dynamics ability that expand process variety our variety some accelerated right this X% our going to question to of clear opportunity in forward. on expect our our in leading that announcement X% Slide we and Bettera Beterra superior provide market. meet as supported for growth gummies, to independent increasing offerings supplements There library, the soft a to and part this partnerships, market the are facilities the X% portion to libraries Bettera. opportunity to wellness to is options X growth significant advance product offerings contributions unparalleled packaging the with suppliers lozenges for needs. and across SOT capacity from product revenue specialized Botanical
a first we $XXX the expect debt-free fiscal this and sales margins close attractive $X within transaction to on the growing over billion this Moving half the transaction annually. its basis, Today, year. we've of premium cash-free approximately to to acquire then company in details, generates it for XX% agreed Bettera at the million offerings reflecting and
acquisition we're in and issuance to bring drawdown Catalent. close. potentially deleveraging of seamlessly experienced similar the expect debt accretive fire earnings Like combination debt pride perspective, other share strategic closing in the and plan At in team acquisitions, formulators partial approximately forward leverage to and of of an for accretive per several term, to the integrating ability talent growth over expect cash We be significantly times expect and approximately in our to with near we we new a our years. medium credit we year to ratio and welcoming hand, the next the recent new the ourselves capabilities, X.X ENI expect the resulting knowledgeable and revolving in and on facility M&A. to its employees From of first at some following significant and looking the acquisition our ample Bettera close of a XXX with of to to We fund at further maintain power Catalent thereafter.
and flight front, work in On detailed the developed streams Bettera's have support for growth and a accelerate leaders already integration integration. plans we’ve identified plan and to
covered share market capability Let as Slide XX. some me now additional trends on and information
As I entry mentioned, gummies, the we’ve right been the seeking soft time. lozenges point chews nutraceutical and into some market
leader manufactures the is and three Importantly, a all in Bettera categories. market across the is independent scale, few today one at of market
for has launches to addition end-to-end ready-to-market accelerate and brands. of In formulations extensive Bettera Bettera’s library developments, manufacturing product partner from solutions commercial packaging, to an
the both ideal chews, plant-based culture, has [indiscernible] ability and with also certifications. is formulations and sensitive a process, produces produce, with Bettera heat Importantly, cold chews organic which to ingredients. Bettera in protecting soft particular for technologies, and using gummy other gelatine soft
customers We for additions health our their and we’re to Catalent as growth product library engine specifically to ask view formats begin in and Bettera working concepts. new product for consumer supplement Our nutritional nutraceutical other high area and and are innovation engaging an gummies excited going this constantly brands emerging about with asking forward. formats customers our for in
times that is of growing today. health investing reasons macro focused innovative market the trends, is delivery the capacity areas also outsourced with in traditional note this market. the that intersection Bettera of two-thirds would consumer of One these the is we on I at pace at believe roughly we're about of four systems constrained
explosive we excess in remains While And the medium grow years. level, market close at market more as the Bettera to the in portion than size large, near its retail the innovative over market $XX today whole future. of expect nutraceuticals doubling last a X billion its to growth delivery the of recent market to the measured to systems segment’s innovative the traditional increased for has
and this at on want in my acquiring leading prides with tradition itself on accretive development subject we we're working I always our by franchises of opening customers. excited room a business. have businesses capabilities. strategic record is Catalent Bettera and conclude integrating employees latest the to manufacturing premium add and Bettera's growth to to and leading CDMO class of example to Finally, comments I'll Catalent saying earnings that world and with growth high emphasize M&A identifying, our track begin successfully high
our of Over the proud service our capabilities across We're work expanding several years, portfolio, last we've offerings. we've and accomplished. transformed capacity the
has never brighter. future looked Our
to we're X% look of note our the projected we be portfolio, X%, achieving the or in coupled range XX% on net remain of meet biologic raising I segments, we I revenue again, previous long-term we all our our to track continued margin expansion. that on in continue segment across of entire from As net we will Based EBITDA XX%. growth confidence consolidated to XX% our rate that in long-term with across growth a segment, our X% from XX% growth to foresee to forecast beat of to the goal revenue XXXX expect which our
confident have our back welcome calls. today believe to are is Catalent helped to in how growth. long-term I'm Tom our our partners We for Castellano employees testament to now and earnings our very a trajectory happy announcement continued and position itself
through as Relations X, on Finance. XXXX the know, you Vice as back, company's of President previously Welcome was Tom. role Operational Tom from Global most as Officer and recent promoted June his As CFO served Investor
